Abstract
In silico methods have been used to identify five different classes of compounds as inhibitors of the essential Plasmodium falciparum enzyme lactate dehydrogenase (LDH). The molecules were assayed for in vitro antimalarial activity in both cell- and enzyme-based inhibition models. 5-Bromo-2-hydroxypyridine-3-carboxylic acid 19 is the most active with IC50 of 3.5 nM for chloroquine sensitive and 5 nM for resistant strains of Plasmodium falciparum, compared to 11 nM and 100 nM for the standard chloroquine. In LDH-enzyme inhibition assays the leading compounds are 5, 10, 18 and 19. Docking studies and the 3D-QSAR technique - CoRIA have been used to identify key binding elements between the molecules and residues in the LDH active site. A bifurcated salt bridge that associates the carboxylate group on the molecules with the guanidino group in the side chain of both Arg109 and Arg171 along with π-stack of the heterocycle with the pyridine ring of the cofactor NAD+, are the prime interactions. In silico ADME/toxicity studies also suggest these molecules have favorable pharmacokinetic and toxicity profiles.
Keywords: Antimalarial agents, CoRIA, docking, lactate dehydrogenase, Plasmodium falciparum, QSAR, Malaria
Anti-Infective Agents
Title: Molecular Modeling Studies, Synthesis and Biological Evaluation of Novel Plasmodium falciparum Lactate Dehydrogenase (pfLDH) Inhibitors
Volume: 10 Issue: 1
Author(s): Premlata K. Ambre, Raghuvir R. S. Pissurlenkar, Ashish S. Jagyasi, Ritesh A. Fule, Vijay Khedkar, Chandrashekar R. Barhate, Livia Vivas, Abhai K. Tripathi, David Sullivan, Richard Birkinshaw, R. Leo Brady, Krishna Iyer and Evans C. Coutinho
Affiliation:
Keywords: Antimalarial agents, CoRIA, docking, lactate dehydrogenase, Plasmodium falciparum, QSAR, Malaria
Abstract: In silico methods have been used to identify five different classes of compounds as inhibitors of the essential Plasmodium falciparum enzyme lactate dehydrogenase (LDH). The molecules were assayed for in vitro antimalarial activity in both cell- and enzyme-based inhibition models. 5-Bromo-2-hydroxypyridine-3-carboxylic acid 19 is the most active with IC50 of 3.5 nM for chloroquine sensitive and 5 nM for resistant strains of Plasmodium falciparum, compared to 11 nM and 100 nM for the standard chloroquine. In LDH-enzyme inhibition assays the leading compounds are 5, 10, 18 and 19. Docking studies and the 3D-QSAR technique - CoRIA have been used to identify key binding elements between the molecules and residues in the LDH active site. A bifurcated salt bridge that associates the carboxylate group on the molecules with the guanidino group in the side chain of both Arg109 and Arg171 along with π-stack of the heterocycle with the pyridine ring of the cofactor NAD+, are the prime interactions. In silico ADME/toxicity studies also suggest these molecules have favorable pharmacokinetic and toxicity profiles.
Export Options
About this article
Cite this article as:
K. Ambre Premlata, R. S. Pissurlenkar Raghuvir, S. Jagyasi Ashish, A. Fule Ritesh, Khedkar Vijay, R. Barhate Chandrashekar, Vivas Livia, K. Tripathi Abhai, Sullivan David, Birkinshaw Richard, Leo Brady R., Iyer Krishna and C. Coutinho Evans, Molecular Modeling Studies, Synthesis and Biological Evaluation of Novel Plasmodium falciparum Lactate Dehydrogenase (pfLDH) Inhibitors, Anti-Infective Agents 2012; 10 (1) . https://dx.doi.org/10.2174/2211362611201010055
DOI https://dx.doi.org/10.2174/2211362611201010055 |
Print ISSN 2211-3525 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-3533 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Endothelial Function: A Surrogate Endpoint in Cardiovascular Studies?
Current Pharmaceutical Design Mangiferin – a Bioactive Xanthonoid, not only from Mango and not just Antioxidant
Mini-Reviews in Medicinal Chemistry Therapeutic Potential of 5-HT7 Receptors in Mood Disorders
Current Drug Targets Neuroprotective Effects of Fisetin in Alzheimer’s and Parkinson’s Diseases: From Chemistry to Medicine
Current Topics in Medicinal Chemistry Docking Prediction for Luteolin Inhibiting TNF-α and NF-κB Pathway
Letters in Drug Design & Discovery Cytoprotective Effect of Phenolic Extract from Brazilian Apple Peel in Insulin-Producing Cells
Current Nutrition & Food Science Biological Importance, Therapeutic Benefit and Analytical Aspects of Bioactive Flavonoid Pectolinarin in the Nature
Drug Metabolism Letters Dietary Polyphenols and Type 2 Diabetes: Current Insights and Future Perspectives
Current Medicinal Chemistry Inactivation of Parathyroid Hormone: Perspectives of Drug Discovery to Combating Hyperparathyroidism
Current Molecular Pharmacology Functional Link Between Adenosine and Insulin: A Hypothesis for Fetoplacental Vascular Endothelial Dysfunction in Gestational Diabetes
Current Vascular Pharmacology Stroke and Neuroinflamation: Role of Sexual Hormones
Current Pharmaceutical Design Indoles - Gut Bacteria Metabolites of Tryptophan with Pharmacotherapeutic Potential
Current Drug Metabolism Pharmacological and Biological Activities of Benzazepines: An Overview
Current Bioactive Compounds Kv7 Channels as Targets for the Treatment of Pain
Current Pharmaceutical Design Recent Developments in the Field of Tumor-Inhibiting Metal Complexes
Current Pharmaceutical Design Interleukin-6 In Rheumatoid Arthritis - From The Laboratory To The Bedside
Current Pharmaceutical Design Pharmacological Management of Type 2 Diabetes Mellitus: An Update
Current Diabetes Reviews ISCHEMIRs: Finding a Way Through the Obstructed Cerebral Arteries
Current Drug Targets Functional Effects of Levosimendan in Rat Basilar Arteries In Vitro
Current Neurovascular Research Selection of Lung Cancer-Specific Landscape Phage for Targeted Drug Delivery
Combinatorial Chemistry & High Throughput Screening